FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019925173> ?p ?o ?g. }

• W2019925173 endingPage "33" @default.
• W2019925173 startingPage "29" @default.
• W2019925173 abstract "Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for 12 months. It causes rapid and prolonged lymphocyte depletion; the consequent homeostatic reconstitution leads to a radically reformed lymphocyte pool with a relative increase in regulatory T cells and expansion of autoreactive T cells. Although previously licensed for the treatment of B-cell chronic lymphocytic leukemia, it is now been considered for licensing in the treatment of multiple sclerosis (MS). From a disappointing experience with alemtuzumab in progressive MS, Alastair Compston and I argued that immunotherapies should be given early in the course of the disease. In a unique program of drug development in MS, alemtuzumab has been compared in 1 phase 2 trial and 2 phase 3 trials with the active comparator interferon beta-1a. In all trials, alemtuzumab was more effective in suppressing relapses than interferon beta-1a. In one phase 2 and one phase 3 trial, alemtuzumab also reduced the risk of accumulating disability compared with interferon beta-1a. Indeed, alemtuzumab treatment led to an improvement in disability and a reduction in cerebral atrophy. The safety issues are infusion-associated reactions largely controlled by methylprednisolone, antihistamines, and antipyretics; mild-to-moderate infections (with 3 opportunistic infections from the open-label experience: 1 case each of spirochaetal gingivitis, pyogenic granuloma, and Listeria meningitis); and autoimmunity. Usually autoimmunity is directed against the thyroid gland, but causes (1 %) immune thrombocytopenia, and in a few cases antiglomerular basement membrane syndrome. Alemtuzumab is an effective therapy for early relapsing-remitting MS, offering disability improvement at least to 5 years after treatment. Its use requires careful monitoring so that potentially serious side effects can be treated early and effectively." @default.
• W2019925173 created "2016-06-24" @default.
• W2019925173 creator A5008022339 @default.
• W2019925173 date "2012-11-27" @default.
• W2019925173 modified "2023-09-27" @default.
• W2019925173 title "Alemtuzumab Therapy for Multiple Sclerosis" @default.
• W2019925173 cites W1975254445 @default.
• W2019925173 cites W1978451233 @default.
• W2019925173 cites W1978822540 @default.
• W2019925173 cites W1989053318 @default.
• W2019925173 cites W2019620441 @default.
• W2019925173 cites W2030522563 @default.
• W2019925173 cites W2038613833 @default.
• W2019925173 cites W2045662685 @default.
• W2019925173 cites W2058002627 @default.
• W2019925173 cites W2069219892 @default.
• W2019925173 cites W2081107613 @default.
• W2019925173 cites W2085899114 @default.
• W2019925173 cites W2087764276 @default.
• W2019925173 cites W2094875942 @default.
• W2019925173 cites W2096611201 @default.
• W2019925173 cites W2101623539 @default.
• W2019925173 cites W2106948231 @default.
• W2019925173 cites W2107422246 @default.
• W2019925173 cites W2112165124 @default.
• W2019925173 cites W2116361650 @default.
• W2019925173 cites W2151735361 @default.
• W2019925173 cites W2163034650 @default.
• W2019925173 cites W2168929134 @default.
• W2019925173 cites W2169182359 @default.
• W2019925173 cites W4250603433 @default.
• W2019925173 doi "https://doi.org/10.1007/s13311-012-0159-0" @default.
• W2019925173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3557360" @default.
• W2019925173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23184314" @default.
• W2019925173 hasPublicationYear "2012" @default.
• W2019925173 type Work @default.
• W2019925173 sameAs 2019925173 @default.
• W2019925173 citedByCount "60" @default.
• W2019925173 countsByYear W20199251732013 @default.
• W2019925173 countsByYear W20199251732014 @default.
• W2019925173 countsByYear W20199251732015 @default.
• W2019925173 countsByYear W20199251732016 @default.
• W2019925173 countsByYear W20199251732017 @default.
• W2019925173 countsByYear W20199251732018 @default.
• W2019925173 countsByYear W20199251732019 @default.
• W2019925173 countsByYear W20199251732020 @default.
• W2019925173 countsByYear W20199251732022 @default.
• W2019925173 countsByYear W20199251732023 @default.
• W2019925173 crossrefType "journal-article" @default.
• W2019925173 hasAuthorship W2019925173A5008022339 @default.
• W2019925173 hasBestOaLocation W20199251732 @default.
• W2019925173 hasConcept C126322002 @default.
• W2019925173 hasConcept C159654299 @default.
• W2019925173 hasConcept C203014093 @default.
• W2019925173 hasConcept C2776036978 @default.
• W2019925173 hasConcept C2777938653 @default.
• W2019925173 hasConcept C2778384904 @default.
• W2019925173 hasConcept C2778461978 @default.
• W2019925173 hasConcept C2779015954 @default.
• W2019925173 hasConcept C2779338263 @default.
• W2019925173 hasConcept C2780640218 @default.
• W2019925173 hasConcept C2780653079 @default.
• W2019925173 hasConcept C2908698914 @default.
• W2019925173 hasConcept C2994247566 @default.
• W2019925173 hasConcept C71924100 @default.
• W2019925173 hasConceptScore W2019925173C126322002 @default.
• W2019925173 hasConceptScore W2019925173C159654299 @default.
• W2019925173 hasConceptScore W2019925173C203014093 @default.
• W2019925173 hasConceptScore W2019925173C2776036978 @default.
• W2019925173 hasConceptScore W2019925173C2777938653 @default.
• W2019925173 hasConceptScore W2019925173C2778384904 @default.
• W2019925173 hasConceptScore W2019925173C2778461978 @default.
• W2019925173 hasConceptScore W2019925173C2779015954 @default.
• W2019925173 hasConceptScore W2019925173C2779338263 @default.
• W2019925173 hasConceptScore W2019925173C2780640218 @default.
• W2019925173 hasConceptScore W2019925173C2780653079 @default.
• W2019925173 hasConceptScore W2019925173C2908698914 @default.
• W2019925173 hasConceptScore W2019925173C2994247566 @default.
• W2019925173 hasConceptScore W2019925173C71924100 @default.
• W2019925173 hasIssue "1" @default.
• W2019925173 hasLocation W20199251731 @default.
• W2019925173 hasLocation W20199251732 @default.
• W2019925173 hasLocation W20199251733 @default.
• W2019925173 hasLocation W20199251734 @default.
• W2019925173 hasOpenAccess W2019925173 @default.
• W2019925173 hasPrimaryLocation W20199251731 @default.
• W2019925173 hasRelatedWork W1972354719 @default.
• W2019925173 hasRelatedWork W1996784496 @default.
• W2019925173 hasRelatedWork W2026336598 @default.
• W2019925173 hasRelatedWork W2036381588 @default.
• W2019925173 hasRelatedWork W2040935430 @default.
• W2019925173 hasRelatedWork W2605414608 @default.
• W2019925173 hasRelatedWork W2910349339 @default.
• W2019925173 hasRelatedWork W2928274480 @default.
• W2019925173 hasRelatedWork W2938848712 @default.
• W2019925173 hasRelatedWork W3085502568 @default.
• W2019925173 hasVolume "10" @default.
• W2019925173 isParatext "false" @default.

• next